Thank you for stopping at our booth, playing games with us and letting us explain to you all about the new world of diagnostics which we are creating for you.
Each year at the annual Conference of European Wound Management Association MESI emphasises the importance of measuring Ankle-Brachial Index in wound care management. Measuring ABI is recognised as the #1 step in wound treatment. It is used to determine the safe level of compression therapy by identifying ulcer type.
We are proud to tell you that more than 700 healthcare professionals visited our booth and walked through the House of Blocked Arteries. We gave away almost 1,000 pairs of MESI socks and measured the ABI of more than 300 people!
Chronic lower extremity ulcers have become a major challenge to healthcare systems worldwide. They last on average 12 to 13 months, recur in up to 60% to 70% of patients, can lead to a loss of function and decreased quality of life and are a significant cause of morbidity. The quickest and easiest possible way to decide on the best management of various types of leg ulcers is by measuring the ankle-brachial index (ABI). With MESI ABPI MD, nurses and physicians are only a minute away from discovering their patient’s potential PAD (Peripheral Arterial Disease). At the same time, and on the basis of the given results, this device also determines the safe level of compression for affected patients.
Predominantly a condition of the elderly, chronic wounds are becoming more prevalent, more difficult to treat and are associated with high treatment costs. Education and training are vital for all those involved in caring for patients with chronic wounds. Because of the speed, ease and accuracy of MESI ABPI MD, our presence and recognition are proving highly significant in every compression therapy and wound care management practice.
The EWMA 2019 was a very significant event for MESI. We presented our traditional MESI ABPI MD and the wireless and completely digital version, the innovative MESI mTABLET ABI. It is equipped with the unique 3CUFF™ technology that provides simultaneous ABI measurement. It also features the indispensable PADsense™ algorithm for detecting severe Peripheral Arterial Disease (PAD).